linjc16/ctgov huggingface dataset:
Laparoscopic Versus Hand Assisted Laparoscopic Trans-peritoneal Laparoscopic Nephrectomy as One Day Surgery (i.e.: Are There Differences in Postoperative Outcome / Convalescence)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to describe the postoperative outcomes after laparoscopic transperitoneal nephrectomy and compare them with hand assisted laparoscopic nephrectomy with a focus on the limiting factors that prevent an ambulatory nephrectomy, and the benefit of our experiences from the previous study to optimize the postoperative outcomes.

Conditions
-----------------
Renal Cancer

Intervention / Treatment
-----------------
* Procedure: Hand assisted laparoscopic nephrectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Patient between 25-80 years old. Diagnosed as Cancer Renis Can read and understand Danish No cardiac disease lead to close cardiologic observations Any T, any N any M stadia. Exclusion criteria: Mentally sick patient Dement Living alone Cardiac problem Per operative bleeding with the need to blood transfusion Operation time at afternoon

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Laparoscopic nephrectomy<br>Patient with renal cell carcenoma will undergo laparoscopic nephrectomy within standarized technique | Procedure: Hand assisted laparoscopic nephrectomy<br>* patients with renal cancer will undergo hans assisted laparoscopic nephrectomy<br>|
| Active Comparator: Hand assisted laparoscopic nephrectomy<br>Patient with renal cell carcenoma will undergo hand assisted laparoscopic nephrectomy | Procedure: Hand assisted laparoscopic nephrectomy<br>* patients with renal cancer will undergo hans assisted laparoscopic nephrectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative hospital admission |  | one day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Laparoscopic nephrectomy, one day surgery
Comparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDS

Study Overview
=================
Brief Summary
-----------------
Smoked marijuana (MJ) and dronabinol (also known as THC or by the trade name Marinol) are used to increase appetite, food intake, and weight in patients with HIV who experience unintended weight loss. This study will compare the effects of MJ and Marinol use in marijuana smokers who are HIV infected.

Detailed Description
-----------------
Little is known about the efficacy and tolerability of oral THC versus smoked MJ in a clinically relevant population. Additionally, it is not clear how THC's effects vary as a function of the duration of treatment or the patient's current patterns of smoked MJ use. This study directly compares 3 doses of smoked marijuana and 3 doses of Marinol across a range of behavioral measures in HIV infected marijuana smokers. Outcome measures will include analysis of food intake, body composition, mood, physical symptoms (e.g., nausea, stomach pain), psychomotor task performance, and sleep.

Official Title
-----------------
THC and Marijuana--Effects in Individuals With HIV/AIDS

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: dronabinol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria HIV infected Smoke marijuana Taking HIV medications Exclusion criteria Naive marijuana smokers People with history of respiratory/pulmonary disease

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: dronabinol|dronabinol to prevent development of marijuana withdrawal|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| daily caloric intake |  | daily measure of colories | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, Marijuana, Marinol, Oral THC, Appetite, Complementary Therapies
Bronchiectasis Effect in COPD Patients

Study Overview
=================
Brief Summary
-----------------
The etiology of bronchiectasis, known as permanent, abnormal, and localized development of bronchi, varies. However, most of them are responsible for infections during childhood. The prevalence of bronchiectasis is particularly high in advanced COPD patients. This phenomenon, called COPD-bronchiectasis overlap syndrome, affects the clinic of COPD patients negatively. In this study; bronchiectasis in respiratory function, exercise capacity, dyspnoea and quality of life in COPD patients.

Detailed Description
-----------------
The etiology of bronchiectasis, known as permanent, abnormal, and localized development of bronchi, varies. However, most of them are responsible for infections during childhood. The prevalence of bronchiectasis is particularly high in advanced COPD patients. This phenomenon, called COPD-bronchiectasis overlap syndrome, affects the clinic of COPD patients negatively. In this study; bronchiectasis in respiratory function, exercise capacity, dyspnoea and quality of life in COPD patients. Torax CTs of patients with COPD who are admitted to the outpatient clinic will be examined. There will be two groups, group 1 in patients with COPD accompanied by bronchiectasis and group 2 in COPD patients without bronchiectasis. In both groups, respiratory function tests, exercise capacities, dyspnea perceptions and quality of life will be evaluated. The data will be compared between the two groups.

Official Title
-----------------
Effect of Bronchiectasis on Respiratory Functions, Exercise Capacity, Dyspnea Perception and Quality of Life in COPD Patients

Conditions
-----------------
Bronchiectasis, Copd

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: above 18 years old clinically stable Exclusion Criteria: other respiratory disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COPD patients<br>COPD patients without bronchiectasis | |
| COPD and bronchiectasis patients<br>COPD patients with bronchiectasis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exercise capacity | six minute walk test | 15 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dyspnea Severity | mMRC Dyspnea Scale (0: no dyspnea, 4: very severe dyspnea) | 5 minutes | 
| Lung Function | Respiratory Function Test | 20 minutes | 
| Health Related Quality of Life | St. George Respiratory Questionnaire (maximum score: 100, lower score means better quality of life) | 25 minutes |
Frequency and Clinical Significance of Renal and Bone Toxicity in HIV-infected Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the frequency of renal and bone toxicity in HIV infected patients receiving antiretroviral therapy, and the outcome in terms of treatment change or/and virological failure, in relation with the presence of classical factors, such as diabetes or hypertension, the role of HIV itself, because of chronic inflammation, and the effects of antiretroviral medication.

Detailed Description
-----------------
This is a retrospective cohort study involving 300 patients to determine the frequency of renal and bone comorbidities/toxicity in a large population of HIV-infected patients receiving antiretroviral therapy, in order to establish the differential role of classical factors, HIV infection, or antiretroviral therapy.

Official Title
-----------------
Frequency and Clinical Significance of Renal and Bone Toxicity in HIV-infected Patients: Role of Classical Factors, HIV Infection, and Antiretroviral Therapy

Conditions
-----------------
Renal Toxicity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed HIV infection Exclusion Criteria: Pregnancy Prior therapy with antineoplastic chemotherapy or chronic treatment with corticosteroids Previous chronic therapy with antiresorptive bone therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Renal and Bone toxicity | Number and percentage of patients with: Confirmed estimated glomerular filtration rate (eGFR) by CKD (chronic kidney disease)-epi equation decrease to < 60 ml/min, or/and More than 25% of eGFR decrease during therapy, or/and Tubular toxicity defined as at least two of confirmed proteinuria (> 300 mg/g), glycosuria with euglycemia, fractional excretion of urinary phosphate > 20%, or of uric acid > 10%. AND Number and percentage of patients with bone mineral density (BMD) decrease > 10% during follow up or progression to osteopenia (from normal) or to osteoporosis (from osteopenia) | Patients will be evaluated for 2 years before | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Consequences of renal or bone toxicity | Percentage of patients with regimen discontinuation (any drug in the regimen) because of renal or/and bone toxicity | Patients will be evaluated for 2 years before | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, antiretroviral, toxicity, eGFR, tubular disease, BMD
Blood and Tissue Sample Collection for Future Colon Cancer Biomarker Studies in Patients Undergoing Colonoscopy

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Collecting and storing samples of blood and tissue from patients undergoing colonoscopy to study in the laboratory may help doctors learn more about colon cancer and identify biomarkers related to colon cancer in the future. PURPOSE: This laboratory study is collecting blood and tissue samples for future colon cancer biomarker studies in patients undergoing colonoscopy.

Detailed Description
-----------------
OBJECTIVES: Collect blood and tissue samples (including polyps, abnormal growths, cancer, and normal tissue) from patients undergoing colonoscopy. OUTLINE: Patients undergo blood and tissue sample collection during colonoscopy. Samples are stored for future biomarker proteomic profiling.

Official Title
-----------------
Discovery of Candidate Biomarkers in Colon Cancer and Precancers Repository

Conditions
-----------------
Colorectal Cancer, Health Status Unknown

Intervention / Treatment
-----------------
* Other: biologic sample preservation procedure
* Procedure: diagnostic colonoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Scheduled for colonoscopy as routine screening or for a specific problem PATIENT CHARACTERISTICS: Not pregnant PRIOR CONCURRENT THERAPY: No concurrent participation in a clinical trial to treat cancer or prevent cancer recurrence

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: biologic sample preservation procedure|nan|
|Procedure: diagnostic colonoscopy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collection of blood and tissue |  | Pre-op & during surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colon cancer, health status unknown
TTHX1114(NM141) in Combination With DWEK/DSO

Study Overview
=================
Brief Summary
-----------------
Open label, single-treatment, with a concurrent non-treatment control

Official Title
-----------------
Phase 2 Study To Determine the Safety and Efficacy of TTHX1114(NM141) on the Regeneration and Migration of Corneal Endothelial Cells in Patients Undergoing DWEK/DSO

Conditions
-----------------
Fuchs' Endothelial Dystrophy, Fuchs Dystrophy, Fuchs

Intervention / Treatment
-----------------
* Drug: TTHX1114(NM141)


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Fuchs Endothelial Cell Dystrophy (FECD) diagnosed more than 6 months Scheduled for DWEK/DSO with a planned central descemetorhexis of approx 4 to 5 mm Subjects in Group 2 must have a stable Fellow Eye with adequate function Key Exclusion Criteria: Secondary corneal/ocular pathology in the Study Eye Prior refractive surgery in the Study Eye Prior exposure to TTHX1114

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Group 1 DWEK/DSO<br>Study subjects in Group 1 will undergo DWEK/ DSO and will not receive any TTHX1114 | |
| Experimental: Group 2 TTHX1114 in combination with DWEK/DSO<br>Study subjects in Group 2 will receive TTHX1114 (5 injections) and undergo DWEK/ DSO | Drug: TTHX1114(NM141)<br>* TTHX1114<br>|
| Experimental: Group 3 TTHX1114 in combination with DWEK/DSO<br>Study subjects in Group 3 will receive TTHX1114 (1 injection) and undergo DWEK/ DSO | Drug: TTHX1114(NM141)<br>* TTHX1114<br>|
| Experimental: Group 1a<br>Study subjects in Group 1a will consist of subjects in Group 1 if not recovered from DWEK/ DSO by Day 84 and will receive TTHX1114 (5 injections) | Drug: TTHX1114(NM141)<br>* TTHX1114<br>|
| Experimental: Group 3a<br>Study subjects in Group 3a will consist of subjects who had participated in in Group 3 if not recovered from DWEK/ DSO by the median time observed in Group 2 and will receive TTHX1114 (4 injections) | Drug: TTHX1114(NM141)<br>* TTHX1114<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best Corrected Visual Acuity | Change from baseline | Day 28 |
Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)

Study Overview
=================
Brief Summary
-----------------
Primary Biliary Cirrhosis (PBC) is a progressive liver disorder of unknown cause. Current evidence suggests that genes, the genetic material we inherit from our parents, in combination with environmental factors, likely play an important role in the development of PBC. This study is being done to investigate whether genes make people more likely to develop PBC. Discovery of these proposed genes will help us better understand how PBC developes, and subsequently, to apply new approaches for its prevention, diagnosis and treatment.

Official Title
-----------------
Understanding the Genetic Predisposition to the Development of Primary Biliary Cirrhosis (PBC).

Conditions
-----------------
Primary Biliary Cirrhosis

Intervention / Treatment
-----------------
* Genetic: Genetic Analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women between the ages of 18-90 who have a history of PBC. PBC patients who have undergone a liver transplant are eligible. Family members (1st degree relatives) of enrolled PBC patients are eligible. Exclusion Criteria: Individuals with no history of PBC or those unable to provide consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: Genetic Analysis|Perform Genome Wide Association Studies.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mapping of Susceptibility Genes in Adult Chronic Cholestatic Liver Diseases | Adult chronic cholestatic liver diseases, such as Primary Biliary Cirrhosis (PBC), are progressive liver disorders of unknown cause. Current evidence suggests that genes, the genetic material we inherit from our parents, in combination with environmental factors, likely play an important role in the development of PBC. This study is being done to investigate whether genes (the inherited genetic material passed from parents to their children) make people more likely to develop PBC. Discovery of these proposed genes will help us to better understand how PBC progresses, and subsequently, to apply new approaches for its prevention, diagnosis and treatment. |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Primary Biliary Cirrhosis, PBC, Cholestatic Liver Disease
Manual Therapy, Exercise and Traction for Patients With Cervical Radiculopathy: A RCT

Study Overview
=================
Brief Summary
-----------------
To date, optimal strategies for the management of patients with Cervical Radiculopathy (CR) remain elusive. The purpose of this study was to compare the effects of manual therapy, exercise, and cervical traction to manual therapy, exercise, and sham traction on pain, function and disability in patients with CR.

Official Title
-----------------
Manual Therapy, Exercise and Traction for Patients With Cervical Radiculopathy: A RCT

Conditions
-----------------
Cervical Radiculopathy

Intervention / Treatment
-----------------
* Other: Sham Traction
* Other: Traction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 3 of 4 positive on CPR, 18-70yrs Exclusion Criteria: history of previous cervical or thoracic spine surgery bilateral upper extremity symptoms signs or symptoms of UMN disease medical red flags(tumor, fracture, rheumatoid arthritis, osteoporosis, prolonged steroid use) cervical spine injections (steroidal) in the past two weeks current use of steroidal medication prescribed for their radiculopathy symptoms

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sham Comparator: II<br>Sham Traction | Other: Sham Traction<br>* Traction <5lbs<br>|
| Active Comparator: I<br>Traction | Other: Traction<br>* Standard supine intermittent traction<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neck Disability Index |  | 2wk, 4wk, 3mo, 6mo | 
| Patient Specific Functional Scale |  | 2wk, 4wk, 3mo, 6mo | 
| Numeric Pain Rating Scale |  | 2wk, 4wk, 3mo, 6mo | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Global Rating Of Change |  | 2wk, 4wk, 3mo, 6mo | 
| Body Diagram |  | 2wk, 4wk, 3mo, 6mo | 
| Fear Avoidance Belief Questionnaire |  | 2wk, 4wk, 3mo, 6mo | 
| Satisfaction |  | 2wk, 4wk, 3mo, 6mo | 
| Grip Strength |  | 2wk, 4wk | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
manual therapy, cervical traction, cervical radiculopathy